Edition:
United States

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

8.70USD
23 May 2018
Change (% chg)

-- (--)
Prev Close
$8.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
15,518
52-wk High
$11.90
52-wk Low
$3.90

Select another date:

Tue, May 15 2018

BRIEF-Aldeyra Therapeutics Announces Q1 Loss Per Share $0.43

* ALDEYRA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Aldeyra Therapeutics Appoints David Mcmullin As Senior Vice President, Corporate Development And Strategy

* ALDEYRA THERAPEUTICS APPOINTS DAVID MCMULLIN AS SENIOR VICE PRESIDENT, CORPORATE DEVELOPMENT AND STRATEGY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Aldeyra Therapeutics Announces First Patient Enrolled In Allergic Conjunctivitis Phase 3 Clinical Trial

* ALDEYRA THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN ALLERGIC CONJUNCTIVITIS PHASE 3 CLINICAL TRIAL

BRIEF-Aldeyra Therapeutics Announces Agreement With Johnson & Johnson Innovation To Advance Novel Immune-Modulating Drugs

* ALDEYRA THERAPEUTICS ANNOUNCES AGREEMENT WITH JOHNSON & JOHNSON INNOVATION TO ADVANCE NOVEL IMMUNE-MODULATING DRUGS FOR SYSTEMIC INFLAMMATORY DISEASES

BRIEF-Aldeyra Therapeutics Announces First Patient Enrolled In Dry Eye Disease Phase 2B Clinical Trial

* ALDEYRA THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN DRY EYE DISEASE PHASE 2B CLINICAL TRIAL Source text for Eikon: Further company coverage:

BRIEF-Aldeyra Therapeutics Posts Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data

* ALDEYRA THERAPEUTICS PRESENTS NONINFECTIOUS ANTERIOR UVEITIS PHASE 2 CLINICAL TRIAL DATA TO THE AMERICAN UVEITIS SOCIETY HELD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2017 ANNUAL MEETING Source text for Eikon: Further company coverage:

Select another date: